期刊文献+

分阶段中药内服联合外洗治疗晚期非小细胞肺癌EGFR-TKIs相关皮疹的临床研究 被引量:19

Clinical Study on Treatment of Advanced Non-small Cell Lung Cancer with EGFR-TKIs Related Rashes by Staged Oral Administration Combined with Chinese Herbs External Washing
在线阅读 下载PDF
导出
摘要 [目的]观察中医辨证论治联合中药外洗治疗晚期非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinaseinhibitor,EGFR-TKI)相关皮疹的临床疗效。[方法]入组出现EGFR-TKI相关皮疹的晚期非小细胞肺癌患者63例,随机分为中医治疗组32例和对照组31例,中医治疗组根据皮疹发展的不同阶段及表现,中医辨证分为风热型(初期)、湿热型(中期)、阴虚型(晚期),分别予消风散、萆薢渗湿汤、沙参麦冬汤内服1剂/日,同时予中药外洗2次/日;对照组予红霉素软膏外用2次/日,合并感染予米诺环素100mg 2次/日口服。治疗疗程均为6周。观察治疗前后皮疹分级与中医临床症状的变化。[结果]中医治疗组有效25例,稳定4例,无效3例,有效率78.13%;对照组有效7例,稳定11例,无效13例,有效率22.6%,中医治疗组较对照组EGFR-TKIs相关皮疹改善明显,差异有统计学意义(P<0.05)。中医治疗组与对照组治疗前肺癌中医症状评分分别为35.38±3.69与34.38±4.21,差异无统计学意义(P>0.05);中医治疗组治疗后中医症状评分为29.59±3.06,较治疗前降低,差异有统计学意义(P<0.05);对照组治疗后中医症状评分为33.29±4.08,较治疗前差异无统计学意义(P>0.05);治疗后中医治疗组中医症状评分优于对照组,差异有统计学意义(P<0.05)。[结论]中医分阶段辨证治疗联合中药外洗能显著改善晚期非小细胞肺癌患者EGFR-TKIs治疗相关皮疹,改善患者的中医临床症状。 [Objective]To observe the clinical efficacy of treatment based on syndrome differentiation combined with herbs external washing in the treatment of epidermal growth factor receptor tyrosine kinase inhibitor-related rash of advanced non-small cell lung cancer(NSCLC).[Methods]Sixty-three advanced non-small cell lung cancer patients with EGFR-TKIs-related rash were randomly divided into two groups. Thirty-two patients were divided into TCM group;thirty-one patients were divided into control group. The TCM group was divided into wind-heat type(initial stage), dampness-heat type(middle stage) and Yin-deficiency type(late stage) according to the differentiation of syndromes and different stages of rash. Xiaofeng Powder, Bixie Shenshi Decoction and Shashen Maidong Decoction were taken of oral administration once a day according to the syndromes differentiation, and herbs washing externally twice a day at the same time. The control group was treated with erythromycin ointment for external use twice a day and minocycline 100 mg twice a day for infection. The course of treatment was 6 weeks. The grade of rash and the change of clinical symptoms were observed before and after treatment. [Results]In the treatment group, 25 cases were effective, 4 cases were stable, 3 cases were ineffective, the efficiency was 78.13%.In the control group, 7 cases were effective, 11 cases were stable, 13 cases were ineffective, the efficiency was 22.6%. The TCM group was significantly better than the control group in EGFR-TKIs related rash(P<0.05).Before treatment, the TCM symptom scores of in TCM group and the control group were 35.38±3.69 and34.38±4.21(P>0.05). After treatment, the score of TCM symptoms in TCM group was 29.59±3.06, which was significantly different from before treatment(P<0.05). In control group, the score of TCM symptoms was 33.29±4.08 after treatment, and there was no significant difference between before and after treatment(P>0.05).After treatment, the TCM symptom scores was significantly different between the two groups(P <0.05). [Conclusion] TCM treatment based on differentiation of symptoms by different stages of rash combined with herbs external washing can significantly relieve the EGFR-TKIs-related rash in advanced non-small cell lung cancer, and relieve the clinical symptoms of TCM.
作者 黄挺 叶知锋 杨雪飞 张志娣 黄伶 郭俊华 HUANG Ting;YE Zhifeng;YANG Xuefei(Hangzhou Hospital of Traditional Chinese Medicine,Hangzhou(310007))
机构地区 杭州市中医院
出处 《浙江中医药大学学报》 CAS 2019年第12期1354-1357,1361,共5页 Journal of Zhejiang Chinese Medical University
关键词 非小细胞肺癌 皮疹 EGFR-TKIS 外治疗法 阶段 辨证论治 non-small cell lung cancer rash EGFR-TKIs external therapy treatment based on syndrome differentiation
  • 相关文献

参考文献8

二级参考文献57

  • 1蒋国,洪小南,樊旼,王佳蕾,傅小龙,钱浩,丁琳.吉非替尼(Iressa)治疗手术、放疗、化疗治疗后失败的非小细胞肺癌的初步报告[J].中国肺癌杂志,2004,7(4):305-308. 被引量:45
  • 2张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 3胡成平.吉非替尼在晚期非小细胞肺癌治疗中的地位.Chest中文版,2005,12(6):3975-3984.
  • 4Fukuoka M, Yano S, Giaccone G, et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-snmll cell lung cancer [J] . J Clin Oncol, 2003, 21 (12): 2237 - 2246.
  • 5KrisMG, NataleRB, HerbstRS, etal. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non - small cell lung cancer: a randomized trial [J] .J Am Med Assoc, 2003, 290 (16) : 2149- 2158.
  • 6王洁.EGFRI相关皮肤不良反应中国临床治疗指导原则.The Oncologist,2007,12:610-621.
  • 7Perez-Soler R,Chachoua A,Hammond LA,et al.Dete-rminants of tumor response and survival with erlotinib in patients with non- small-cell lung cancer.J Clin Oncol, 2004,22:3238-3247.
  • 8Bezjak A,Tu D,Seymour L,et al.Symptom improvement in lung cancer patients treated with erlotinib:quality of life analysis Of the National Cancer Institute of Canada Clinical Trials Group Studv BR. 21.J Clin Oncol , 2006,24:3831-3837.
  • 9Thomas J,Lynch Jr,Ed S Kim,et al.Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities:An Evolving Paradigm in Clinical Management.The Oncologist,2007,12:610-621.
  • 10Park, Keunchil,Goto, K et al.A review of the benefit risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Current Medical Research and Opinion, 2006,3(22):561-573.

共引文献4613

同被引文献286

引证文献19

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部